EUVIMEDEUVIMED entdecken
Crossref

Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies

Azhar Hussain, Jack Moniot, Mohsena Sumaya, David M Hughes

NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026

DOI: 10.67209/ifmf1317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Azhar Hussain und 3 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is the second most common hematologic malignancy in high-income countries, accounting for approximately 17% of hematologic cancers. MM incidence has increased by 143% since 1975, and up to 50% of patients present with renal impairment at diagnosis. The American Cancer Society estimates that 36,110 new cases of MM will occur in the United States of America this year, resulting in 12,030 deaths. Renal dysfunction complicates treatment and independently worsens prognosis, emphasizing the importance of prompt intervention for optimal outcomes.

Zitieren

APA

Hussain, A., Moniot, J., Sumaya, M., & Hughes, D. M. (2026). Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/ifmf1317

Vancouver

Hussain A, Moniot J, Sumaya M, Hughes DM. Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/ifmf1317

BibTeX
@article{Hussain2026,
  author = {Hussain, Azhar and Moniot, Jack and Sumaya, Mohsena and Hughes, David M},
  title = {Renal dysfunction in multiple myeloma: pathogenesis, diagnosis, and pharmacist-led care strategies},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/ifmf1317}
}
Kostenlos starten →